Page last updated: 2024-09-05

deferasirox and er-086526

deferasirox has been researched along with er-086526 in 1 studies

Compound Research Comparison

Studies
(deferasirox)
Trials
(deferasirox)
Recent Studies (post-2010)
(deferasirox)
Studies
(er-086526)
Trials
(er-086526)
Recent Studies (post-2010) (er-086526)
832136572567113517

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Amano, R; Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Shibutani, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S1

Other Studies

1 other study(ies) available for deferasirox and er-086526

ArticleYear
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    BMC cancer, 2020, Dec-10, Volume: 20, Issue:1

    Topics: Animals; Antigens, CD; B7-H1 Antigen; Cadherins; Cell Cycle; Cell Line, Tumor; Deferasirox; Deferoxamine; Epithelial-Mesenchymal Transition; Female; Furans; Humans; Iron; Iron Chelating Agents; Iron Deficiencies; Ketones; Mice; Mice, Inbred BALB C; Mice, Nude; RNA, Messenger; RNA, Neoplasm; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Microenvironment; Xenograft Model Antitumor Assays

2020